Nasdaq · Healthcare
Zai Lab Ltd (ZLAB)
As-reported financials and recent SEC filings for Zai Lab Ltd, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$457.2M
Net income
$-175.5M
Net margin
-38.4%
Diluted EPS
$-0.16
ROE
-24.5%
P/E (TTM)
—
Market cap
$2.03B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $457.2M | $397.6M | $266.7M | $212.7M | $144.1M |
| Gross profit | $266.7M | $250.5M | $170.9M | $138.7M | $91.9M |
| Operating income | $-229.4M | $-282.1M | $-366.6M | $-404.4M | $-700.1M |
| Net income | $-175.5M | $-257.1M | $-334.6M | $-443.3M | $-704.5M |
| Diluted EPS | $-0.16 | $-0.26 | $-0.35 | $-0.46 | $-0.76 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-26
View on EDGAR →1442026-06-26
View on EDGAR →1442026-06-26
View on EDGAR →42026-06-24
View on EDGAR →1442026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →Go deeper on ZLAB
Search Zai Lab Ltd’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.